Pharmaceuticals giant GlaxoSmithKline announced on Friday afternoon that it has completed, along with partner Theravance, the phase III programme of a 52-week safety study for its UMEC/VI medicine for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
The 6,000-patient study, along with other recently completed studies, "supports GSK's plans to commence global regulatory submissions for UMEC/VI from the end of 2012," the firm said.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Average earnings by region – how does your income compare?There are significant regional differences when it comes to how much the average worker earns. We explore the data and reveal where in the UK average earnings are highest.
-
St James’s Place confirms new fees – what it means for customersThe UK’s largest wealth manager is replacing its “opaque” and “complex” pricing structure. We explain the new charges, and when they will kick in
